ENERTIVA
TIRZEPATIDE 60mg / 3mL
Product details are available publicly. Please log in to view pricing and place an order.
Login to View PriceTesting & COA
View HistoryFor professional research catalog display only.
- Tirzepatide is a dual incretin receptor agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways. By simultaneously activating these metabolic signaling systems, it supports enhanced glycemic control, appetite regulation, and energy balance.
- This dual-mechanism approach distinguishes tirzepatide from traditional single-pathway GLP-1 therapies, offering a broader metabolic impact. It plays a role in improving insulin sensitivity, modulating gastric emptying, and influencing satiety signaling, making it highly relevant in metabolic-focused protocols.
- Manufactured under controlled, high purity standards, tirzepatide is designed for consistency and stability across batches. Its defined structure and reproducibility support clinical environments and structured metabolic programs where precision and reliability are essential.
